Medical College of Wisconsin
This is an intervention targeting patients at risk for non-adherence to endocrine therapy after primary treatments for hormone-positive breast cancer. In a randomized study, the study team will collect patient-reported symptoms monthly from participants through surveys. Pharmacists who specialize in cancer at the patients' hospital will give patients recommendations to help improve their symptoms and address other barriers so they can continue daily endocrine therapy medications.
This study will test whether oncology teams can adapt and combine models from intensive oncologic care and chronic noncancer care to support long-term oral oncologic medication adherence through better symptom monitoring and management. It will identify patients at risk of nonadherence through electronic health records and target them with a symptom monitoring and management intervention. The study will use patient-reported outcomes (PROs) to identify symptoms that may cause nonadherence and will involve clinical pharmacist-led follow-up. Objectives: 1. Assess the impact of the intervention…
Inclusion Criteria: * Cisgender women assigned female at birth * Age 18 years or older * Stage 1-3 hormone receptor-positive breast cancer 1. Premenopausal patients being treated with GNRH agonist/antagonist to induce menopause are eligible 2. Patients who received treatment with CDK 4/6 inhibitors are eligible * Recommended to continue AET for ≥2 additional years after enrollment * Low adherence defined as prescription fills with a proportion of days covered (PDC) of \<80%, examined over all fills during the 2 years prior to date of eligibility review since the first AET prescription/da…
Patients in the intervention phase will receive PRO-based symptom monitoring once a month and pharmacist-led management for problematic symptoms based on routine clinical care recommendations.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.